Indications for Liver Transplantation

  • Alessandro CucchettiEmail author
  • Ranka Vukotic
  • Pietro Andreone
  • Fabio Piscaglia
  • Anna Pecorelli
  • Luigi Bolondi
  • Maria Cristina Morelli
  • Giorgio Ercolani
  • Matteo Cescon
  • Matteo Ravaioli
  • Massimo Del Gaudio


The list of indications for liver transplantation (LT) includes irreversible causes of end-stage liver disease which are curable by the procedure. More than a decade ago, the American Association for the Study of the Liver Disease (AASLD) established minimal listing criteria for patients with end-stage liver disease. To qualify for waiting list, the 1 year expected survival should be <90 % without LT. Liver transplantation should lead to prolonged survival and/or an improved quality of life [10]. Indications can be segregated into two classes: (1) acute conditions leading to a rapid and irreversible liver failure and (2) chronic diseases that can lead to liver failure and/or complications of end-stage liver disease. In the present introduction, causes of acute liver failure were discussed, whereas in the following chapters, each indication for LT was reported and analyzed.


Liver Transplantation Sustained Virological Response Primary Biliary Cirrhosis Primary Sclerosing Cholangitis Biliary Atresia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    US Scientific Registry (UNOS). Richmond (VA): United Network for Organ Sharing. 2014.
  2. 2.
    Lee WM. Acute liver failure. NEJM. 1993;329:1862–72.PubMedGoogle Scholar
  3. 3.
    Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med. 2003;31:299–305.PubMedGoogle Scholar
  4. 4.
    O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–45.PubMedGoogle Scholar
  5. 5.
    Macquillan GC, Seyam MS, Nightingale P, Neuberger JM, Murphy N. Blood lactate but not serum phosphate levels can predict patient outcome in fulminant hepatic failure. Liver Transpl. 2005;11:1073–9.PubMedGoogle Scholar
  6. 6.
    Nazer H, Ede RJ, Mowat AP, Williams R. Wilson’s disease: clinical presentation and use of prognostic index. Gut. 1986;27:1377–81.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11:441–8.PubMedGoogle Scholar
  8. 8.
    Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387–94.PubMedGoogle Scholar
  9. 9.
    Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis. 2010;12:292–308.PubMedGoogle Scholar
  10. 10.
    Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992;33:1390–6.PubMedCentralPubMedGoogle Scholar
  11. 11.
    O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104–11.PubMedGoogle Scholar
  12. 12.
    Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for waitlisted and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–60.PubMedGoogle Scholar
  13. 13.
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100.PubMedGoogle Scholar
  14. 14.
    Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.PubMedGoogle Scholar
  15. 15.
    Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001–6.PubMedGoogle Scholar
  16. 16.
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.PubMedGoogle Scholar
  17. 17.
    Cholongitas E, Goulis J, Akriviadis E, et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176–90.PubMedGoogle Scholar
  18. 18.
    Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6:696–700.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587–93.PubMedGoogle Scholar
  20. 20.
    Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212–9.PubMedGoogle Scholar
  21. 21.
    Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35:176–81.PubMedGoogle Scholar
  22. 22.
    EASL. Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.Google Scholar
  23. 23.
    Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272–9.PubMedGoogle Scholar
  24. 24.
    Adam R, McMaster P, O’Grady JG, European Liver Transplant Association, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9(12):1231–43.PubMedGoogle Scholar
  25. 25.
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680–7.PubMedGoogle Scholar
  26. 26.
    Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192–204.PubMedGoogle Scholar
  27. 27.
    Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852–8.PubMedGoogle Scholar
  28. 28.
    Carrión JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746–56.PubMedGoogle Scholar
  29. 29.
    Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426–33.PubMedGoogle Scholar
  30. 30.
    Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766–77.PubMedGoogle Scholar
  31. 31.
    Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679–87.PubMedGoogle Scholar
  32. 32.
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.PubMedGoogle Scholar
  33. 33.
    Jacobson IM, McHutchison JG, Dusheiko G, ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.PubMedGoogle Scholar
  34. 34.
    Zeuzem S, Andreone P, Pol S, REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.PubMedGoogle Scholar
  35. 35.
    Werner CR, Egetemeyr DP, Lauer U, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012;18:1464–70.PubMedGoogle Scholar
  36. 36.
    Burton Jr JR, O’Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014. doi: 10.1016/j.jhep.2014.04.037. pii: S0168-8278(14)00300-6.Google Scholar
  37. 37.
    Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int. 2014;34 Suppl 1:46–52. doi: 10.1111/liv.12406.PubMedGoogle Scholar
  38. 38.
    Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60(1):78–86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.PubMedGoogle Scholar
  39. 39.
    Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012;56(11):5728–34. doi: 10.1128/AAC.01151-12. Epub 2012 Aug 20.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation. J Hepatol. 2014;60(4):894–6.PubMedGoogle Scholar
  41. 41.
    Coilly A, Sebagh M, Duclos-Vallée JC. Reply to: “frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation”. J Hepatol. 2014;60(4):896–7. doi: 10.1016/j.jhep.2013.11.032.PubMedGoogle Scholar
  42. 42.
    Saxena V, Monto A, Terrault N. Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals – authors’ reply. Aliment Pharmacol Ther. 2014;39(12):1428. doi: 10.1111/apt.12775.PubMedGoogle Scholar
  43. 43.
    Roche B, Samuel D. Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. Liver Transpl. 2011;17:488–91.PubMedGoogle Scholar
  44. 44.
    Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53:317–24.PubMedGoogle Scholar
  45. 45.
    Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322–7.PubMedGoogle Scholar
  46. 46.
    Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant. 2011;11:1051–7.PubMedGoogle Scholar
  47. 47.
    Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577–85.PubMedGoogle Scholar
  48. 48.
    ReViS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation. 2011;92:334–40.Google Scholar
  49. 49.
    Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol. 2013;29(3):243–9.PubMedGoogle Scholar
  50. 50.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEJM. 2013;368:34–44.PubMedGoogle Scholar
  51. 51.
    Forns X, Fontana RJ, Moonka D, et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. 64th annual meeting of the American Association for the Study of Liver Diseases. 2013.Google Scholar
  52. 52.
    Samuel D, Charlton M, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis c infection after liver transplantation: results of a prospective, multicenter study. Gastroenterol. 2015;148(1):108–17.
  53. 53.
    Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers (abstract 1869). 63rd annual meeting of the American Association for the Study of Liver Diseases. 2012.Google Scholar
  54. 54.
    Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39:478–87.PubMedGoogle Scholar
  55. 55.
    Vukotic R, Morelli MC, Pinna AD, et al. Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients. Aliment Pharmacol Ther. 2014. doi: 10.1111/apt.12853.PubMedGoogle Scholar
  56. 56.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Lyon, France: International Agency for Research on Cancer; 2013 [Internet]. Available from: Cited 2014 Mar 22.
  57. 57.
    Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Digestive diseases [Internet] 2009. Available from:
  58. 58.
    Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.PubMedGoogle Scholar
  59. 59.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedGoogle Scholar
  60. 60.
    European Liver Transplant Registry. Mortality and retransplantation. 2012. Accessed 27 Aug 2012.
  61. 61.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedGoogle Scholar
  62. 62.
    Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.PubMedGoogle Scholar
  63. 63.
    Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.PubMedGoogle Scholar
  64. 64.
    Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.PubMedGoogle Scholar
  65. 65.
    Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Del Gaudio M, Cucchetti A, Pinna AD. Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol. 2014;20(18):5345–52.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D’Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150–9.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.PubMedGoogle Scholar
  69. 69.
    OPTN – Organ Procurement and Transplantation policy 3.6. Liver transplant candidates with hepatocellular carcinoma. Updated 31 Oct 2013. Available at
  70. 70.
    Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609–18.PubMedGoogle Scholar
  71. 71.
    European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.Google Scholar
  72. 72.
    Cucchetti A, Vitale A, Del Gaudio M, Ravaioli M, Ercolani G, Cescon M, Zanello M, Morelli MC, Cillo U, Grazi GL, Pinna AD. Harm benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant. 2010;10(3):619–27. doi: 10.1111/j.1600-6143.2009.02984. Epub 2010 Jan 29. PubMed.PubMedGoogle Scholar
  73. 73.
    Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250(6):922–8.PubMedGoogle Scholar
  74. 74.
    Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, Ghobrial RM, Fair JH, Olthoff KM, Kam I. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601–8.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl. 2009;15:1861–6 [PubMed] [DOI].PubMedGoogle Scholar
  76. 76.
    Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143(2):182–8.PubMedGoogle Scholar
  77. 77.
    Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–8.PubMedGoogle Scholar
  78. 78.
    Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006;55(4):536–41.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chretien Y, Poupon RE, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 2004;24:187–93.PubMedGoogle Scholar
  80. 80.
    Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and bio- chemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol. 1999;30:408–12.PubMedGoogle Scholar
  81. 81.
    Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983;308:1–7.PubMedGoogle Scholar
  82. 82.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.Google Scholar
  83. 83.
    Locke III GR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996;23:52–6.PubMedGoogle Scholar
  84. 84.
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–90.PubMedGoogle Scholar
  85. 85.
    Lee J, Belanger A, Joucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:1313–5.PubMedGoogle Scholar
  86. 86.
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103.PubMedGoogle Scholar
  87. 87.
    Lindstrom L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzen H, Sangfelt P, Rydning A, Folvik G, Gangsoy-Kristiansen M, Danielsson A, Bergquist A. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012;35:451–7.PubMedGoogle Scholar
  88. 88.
    Jorgensen KK, Lindstrom L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol. 2012;8–9:1021–9.Google Scholar
  89. 89.
    Wiesner RH. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. Mayo Clin Proc. 1998;73:575–88.PubMedGoogle Scholar
  90. 90.
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–7.PubMedGoogle Scholar
  91. 91.
    Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980;21:78–83.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Haber BA, Erlichman J, Loomes KM. Recent advances in biliary atresia: prospects for novel therapies. Expert Opin Investig Drugs. 2008;17(12):1911–24 [Medline].PubMedGoogle Scholar
  93. 93.
    Drut R, Dut RM, Gomez MA, Rua EC, Lojo MM. Presence of human papillomavirus in extrahepatic biliary atresia. J Pediatr Gastroenterol Nutr. 1998;27:530–5.PubMedGoogle Scholar
  94. 94.
    Domiati-Saad R, Dawson DB, Margraf LR, Finegold MJ, Weinberg AG, Rogers BB. Cytomegalovirus and human herpesvirus 6, but not human papillomavirus, are present in neonatal giant cell hepatitis and extrahepatic biliary atresia. Pediatr Dev Pathol. 2000;3:367–73.PubMedGoogle Scholar
  95. 95.
    Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955–1967). J Am Coll Surg. 2002;195:587–610.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEJM. 1996;334:693–9.PubMedGoogle Scholar
  97. 97.
    Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, Freise CE, Kam I, Pruett TL, Everhart JE, Hulbert-Shearon TE, Gillespie BW, Emond JC. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg. 2005;242:314–23.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Pichlmayr R, Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, Ringe B. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg. 1996;224:628–38.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Becker NS, Rodriguez JA, Barshes NR, O’Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg. 2008;12:117–22.PubMedGoogle Scholar
  100. 100.
    Robles R, Figueras J, Turrión VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Valdecasas JC, López P, Gómez M, de Vicente E, Loinaz C, Santoyo J, Fleitas M, Bernardos A, Lladó L, Ramírez P, Bueno FS, Jaurrieta E, Parrilla P. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239:265–71.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 1999;44:121–6.PubMedGoogle Scholar
  102. 102.
    De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6:309–16.PubMedGoogle Scholar
  103. 103.
    Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw Jr B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002;2:774–9.PubMedGoogle Scholar
  104. 104.
    Gu J, Bai J, Shi X, Zhou J, Qiu Y, Wu Y, Jiang C, Sun X, Xu F, Zhang Y, Ding Y. Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2012;130:2155–63.PubMedGoogle Scholar
  105. 105.
    Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom? J Hepatol. 2007;47:455–9.PubMedGoogle Scholar
  106. 106.
    Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. Hepatobiliary Pancreat Sci. 2010;17:476–89.Google Scholar
  107. 107.
    Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, Nagino M. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg. 2013;257:718–25.PubMedGoogle Scholar
  108. 108.
    Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.PubMedGoogle Scholar
  109. 109.
    Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807–15.PubMedGoogle Scholar
  110. 110.
    Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47:460–6.PubMedGoogle Scholar
  111. 111.
    Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, Cherqui D, Castaing D, Ruszniewski P, Wolf P, Paye F, Salame E, Muscari F, Pruvot FR, Baulieux J. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8:1205–13.PubMedGoogle Scholar
  112. 112.
    Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, Hundley JC. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146:953–8.PubMedGoogle Scholar
  113. 113.
    Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–6.PubMedGoogle Scholar
  114. 114.
    Cruz Jr RJ, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw PH, Haberman K, Krishnamurti L, Marsh JW, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery. 2013;153:150–9.PubMedGoogle Scholar
  115. 115.
    Ercolani G, Grazi GL, Pinna AD. Liver transplantation for benign hepatic tumors: a systematic review. Dig Surg. 2010;27:68–75.PubMedGoogle Scholar
  116. 116.
    Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–21.PubMedGoogle Scholar
  117. 117.
    Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010;16:930–42.PubMedGoogle Scholar
  118. 118.
    Schwartz ME, Roayaie S, Konstadoulakis MM, Gomatos IP, Miller CM. The Mount Sinai experience with orthotopic liver transplantation for benign tumors: brief report and literature review: case reports. Transpl Proc. 2008;40:1759–62.Google Scholar
  119. 119.
    Dimick JB, Cowan JA, Knol JA, et al. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg. 2003;138:185–91.PubMedGoogle Scholar
  120. 120.
    UNOS database, based on OPTN data as of May 15th, 2009 (
  121. 121.
    ELTR database, update to December 31st, 2008 (
  122. 122.
    Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology. 2004;40:774–82.PubMedGoogle Scholar
  123. 123.
    Cavallari G, Nardo B, Montalti R, et al. Combined liver-kidney transplantation: experience at Bologna’s transplant center. Transpl Proc. 2004;36:541–2.Google Scholar
  124. 124.
    Lerut J, Ciccarelli O, Rutgers M, et al. Liver transplantation with preservation of the inferior vena cava in case of symptomatic adult polycystic disease. Transpl Int. 2005;18:513–8.PubMedGoogle Scholar
  125. 125.
    Ueno T, Barri Y, Netto G, et al. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation. 2006;82:501–7.PubMedGoogle Scholar
  126. 126.
    Kirchner G, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl. 2006;12:1268–77.PubMedGoogle Scholar
  127. 127.
    Rosenberg L. The risk of liver neoplasm in relation to combined oral contraceptives use. Contraception. 1991;43(6):643–52.PubMedGoogle Scholar
  128. 128.
    Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol. 2008;15:2795–803.PubMedGoogle Scholar
  129. 129.
    Dokmak S, Paradis V, Vilgrain V, et al. A single center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137(5):1698–705.PubMedGoogle Scholar
  130. 130.
    Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology. 1985;89:1132–8.PubMedGoogle Scholar
  131. 131.
    Cliché L, Dao T, Salamè E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management. Ann Surg. 2000;231:74–81.Google Scholar
  132. 132.
    Vetelainen R, Erdogan D, De Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int. 2008;28(4):499–508.Google Scholar
  133. 133.
    Bioulac-Sage P, Laumonier H, Laurent C, Blanc JF, Balabaud C. Benign and malignant vascular tumors of the liver in adults. Sem Liv Dis. 2008;28:302–14.Google Scholar
  134. 134.
    Ferraz A, Sette M, Maia M, et al. Liver transplant for the treatment of giant hepatic hemangioma. Liver Transpl. 2004;10:1436–7.PubMedGoogle Scholar
  135. 135.
    Todani T, Watanabe Y, Narusue M, Tabuchi K, Okajima K. Congenital bile ducts cysts: classification, operative procedures and review of thirty-seven cases, including cancer arising from choledochal cyst. Am J Surg. 1977;134:263–9.PubMedGoogle Scholar
  136. 136.
    Habib S, Shakil O, Couto O, et al. Caroli’s disease and orthotopic liver transplantation. Liver Transpl. 2006;12:416–21.PubMedGoogle Scholar
  137. 137.
    De Kerckhove L, De Meyer M, Verbaandert C, et al. The place of liver transplantation in Caroli’s disease and syndrome. Transpl Int. 2006;19:381–8.PubMedGoogle Scholar
  138. 138.
    Herraiz A, Torres-Quevedo R, Pallardo J. Transplante hepatico en pacientes con lesiones hepaticas benignas. Cir Esp. 2008;84:60–6.Google Scholar
  139. 139.
    Hernandez JC, Alfonso C, Gonzales L, et al. Solid mesenchymal hamartoma in an adult: a case report. J Clin Pathol. 2006;59:542–5.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Bresson-Hadni S, Koch S, Miguet JP, et al. Indications and results of liver transplantation for echinococcus alveolar infection. Lang Arch Surg. 2003;388:231–8.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Alessandro Cucchetti
    • 1
    Email author
  • Ranka Vukotic
    • 1
  • Pietro Andreone
    • 1
  • Fabio Piscaglia
    • 1
  • Anna Pecorelli
    • 1
  • Luigi Bolondi
    • 1
  • Maria Cristina Morelli
    • 2
  • Giorgio Ercolani
    • 1
  • Matteo Cescon
    • 1
  • Matteo Ravaioli
    • 3
  • Massimo Del Gaudio
    • 3
  1. 1.Department of Medical and Surgical Sciences – DIMECAlma Mater Studiorum – University of BolognaBolognaItaly
  2. 2.UO Internal Medicine for the Treatment of Severe Organ InsufficiencyOrgan Insufficiency and TransplantationBolognaItaly
  3. 3.General and Transplant Surgical UnitSt. Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations